by Amy Mek, RAIR Foundation:
The parallels between the bird flu ‘vaccine’ push and the COVID-19 ‘vaccine’ campaign reveal a coordinated effort to capitalize on health crises for profit and control
In a concerning development that echoes the recent COVID-19 “vaccine” saga, pharmaceutical giant Moderna has secured a whopping $176 million from the U.S. government to fast-track the development of a new mRNA flu vaccine. This vaccine is purportedly designed to protect against both seasonal influenza and bird flu viruses currently circulating in the United States. As Moderna prepares to kick off clinical trials next year, working closely with the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA), questions arise about the true motives and implications of this massive investment.
TRUTH LIVES on at https://sgtreport.tv/
Government’s Growing Concerns
The U.S. Department of Health and Human Services (HHS) has expressed “serious concerns” about a potential health crisis stemming from an avian flu outbreak. With the virus continuing to spread among mammals, there is a so-called “looming threat” of a new pandemic “if” it manages to jump to humans. This scenario, as reported by The Telegraph, has fueled the urgency behind the government’s investment in Moderna’s new gene therapy injection, marketed as a ‘vaccine’.
However, while globalists pretend to be trying to protect the public from this “looming threat,” their actions suggest a more sinister goal. The push for viruses to jump from mammals to humans could further harm farmers and lead to the destruction of animals that form a crucial part of the human diet. This would devastate traditional farming communities and pave the way for the promotion of lab-grown meat and bugs, aligning with the globalist agenda of controlling the food supply. By undermining natural food sources, they aim to steer the population towards synthetic alternatives, thereby increasing their grip on what people consume and furthering their control over the masses.
Moderna’s Financial Woes
This investment comes at a critical time for Moderna. In the first quarter of this year, the company reported a staggering billion-dollar loss, as the demand for coronavirus “vaccines” has nearly vanished. Moderna’s revenue plummeted by 91 percent to a mere $167 million, a sharp contrast to the over $19 billion generated from COVID-19 shots in 2022. This financial downturn has led the company to seek new revenue streams, and the avian flu injections appears to be the next goldmine.
A New Goldmine for Vaccine Makers?
Moderna isn’t the only player in this game. Reports suggest that the U.S. government is also in talks with Pfizer about developing an mRNA vaccine against the avian flu virus. Pfizer, another major beneficiary of the COVID-19 “vaccine” boom, is similarly on the lookout for new lucrative opportunities. The financial motivations behind these developments cannot be ignored, especially considering the immense profits both companies reaped from their COVID-19 injections.
European Union’s Involvement
The situation extends beyond the United States. Last month, the European Union signed a contract for the delivery of over 40 million bird flu vaccines to 15 countries, with the first shipment headed to Finland. This large-scale procurement is an indicator of the growing global hysteria over avian flu and the potential for their new much desired pandemic.
Setting the Tone: A Warning for the Public
The parallels between the current push for an avian flu gene therapy marketed as a ‘vaccine’ and the recent COVID-19 vaccine campaign are striking. The rapid mobilization of resources, the significant financial investments, and the involvement of major pharmaceutical companies all point towards a coordinated effort to capitalize on a new health crisis. The public should be wary of the motivations behind these developments, as the financial interests of big pharma and globalist agendas seem to take precedence over genuine public health concerns.
Read More @ RAIRFoundation.com
